221 related articles for article (PubMed ID: 8184174)
1. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
Candrina R
Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
[TBL] [Abstract][Full Text] [Related]
2. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
4. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
5. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
6. Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
Harinarayan CV
J Indian Med Assoc; 2004 May; 102(5):258, 260-1. PubMed ID: 15636029
[TBL] [Abstract][Full Text] [Related]
7. Medical management of acromegaly--what and when?
Melmed S
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():13-7. PubMed ID: 8372605
[TBL] [Abstract][Full Text] [Related]
8. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
9. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
Barakat S; Melmed S
Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
[TBL] [Abstract][Full Text] [Related]
10. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
[TBL] [Abstract][Full Text] [Related]
11. Medical management of acromegaly: effects of SMS 201-995 in 30 patients.
Pagani G; Montini M; Gianola D; Pagani MD; Tengattini F; Dominoni P; Ghilardi G; Cortesi L; Pedroncelli A; Tonnarelli GP
Endocrinol Exp; 1990 Mar; 24(1-2):175-85. PubMed ID: 2361459
[TBL] [Abstract][Full Text] [Related]
12. Evidence supporting surgery as treatment of choice for acromegaly.
Fahlbusch R; Honegger J; Buchfelder M
J Endocrinol; 1997 Oct; 155 Suppl 1():S53-5. PubMed ID: 9389996
[TBL] [Abstract][Full Text] [Related]
13. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
Turner HE; Thornton-Jones VA; Wass JA
Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
[TBL] [Abstract][Full Text] [Related]
14. Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study.
Bogazzi F; Di Bello V; Palagi C; Donne MG; Di Cori A; Gavioli S; Talini E; Cosci C; Sardella C; Brogioni S; Mariani M; Martino E
Clin Endocrinol (Oxf); 2005 May; 62(5):590-6. PubMed ID: 15853830
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of octreotide LAR as firstline therapy for patients with newly diagnosed acromegaly is independent of tumor extension: predictive factors of tumor and biochemical response.
Luque-Ramírez M; Portoles GR; Varela C; Albero R; Halperin I; Moreiro J; Soto A; Casamitjana R;
Horm Metab Res; 2010 Jan; 42(1):38-44. PubMed ID: 19798622
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes and mortality of 94 patients with acromegaly.
Trepp R; Stettler C; Zwahlen M; Seiler R; Diem P; Christ ER
Acta Neurochir (Wien); 2005 Mar; 147(3):243-51; discussion 250-1. PubMed ID: 15627919
[TBL] [Abstract][Full Text] [Related]
17. Octreotide treatment of acromegaly. A randomized, multicenter study.
Ezzat S; Snyder PJ; Young WF; Boyajy LD; Newman C; Klibanski A; Molitch ME; Boyd AE; Sheeler L; Cook DM
Ann Intern Med; 1992 Nov; 117(9):711-8. PubMed ID: 1416572
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acromegaly with octreotide: effectiveness and tolerability of its pulsatile administration by portable pump.
Giusti M; Cuttica CM; Cariola G; Valenti S; Sessarego P; Giordano G
Recenti Prog Med; 1995 May; 86(5):189-94. PubMed ID: 7604174
[TBL] [Abstract][Full Text] [Related]
19. Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.
Gradiser M; Matovinovic M; Vrkljan M
Croat Med J; 2007 Feb; 48(1):87-91. PubMed ID: 17309144
[TBL] [Abstract][Full Text] [Related]
20. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
Minniti G; Jaffrain-Rea ML; Osti M; Esposito V; Santoro A; Solda F; Gargiulo P; Tamburrano G; Enrici RM
Clin Endocrinol (Oxf); 2005 Feb; 62(2):210-6. PubMed ID: 15670198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
